These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 24650468)

  • 1. Diagnosis and treatment of lymph node metastases in pediatric rhabdomyosarcoma in the Netherlands: a retrospective analysis.
    Terwisscha van Scheltinga CE; Spronk P; van Rosmalen J; Wijnen MH; Heij HA; van Baren R; Merks JH; van Noesel MM; Wijnen RM
    J Pediatr Surg; 2014 Mar; 49(3):416-9. PubMed ID: 24650468
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic factors and surgical treatment guidelines for children with rhabdomyosarcoma of the perineum or anus: a report of Intergroup Rhabdomyosarcoma Studies I through IV, 1972 through 1997.
    Blakely ML; Andrassy RJ; Raney RB; Anderson JR; Wiener ES; Rodeberg DA; Paidas CN; Lobe TE; Crist WM;
    J Pediatr Surg; 2003 Mar; 38(3):347-53. PubMed ID: 12632347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group.
    Meza JL; Anderson J; Pappo AS; Meyer WH;
    J Clin Oncol; 2006 Aug; 24(24):3844-51. PubMed ID: 16921036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of children with nonmetastatic paratesticular rhabdomyosarcoma: results of the Malignant Mesenchymal Tumors studies (MMT 84 and MMT 89) of the International Society of Pediatric Oncology.
    Stewart RJ; Martelli H; Oberlin O; Rey A; Bouvet N; Spicer RD; Godzinski J; Stevens MC;
    J Clin Oncol; 2003 Mar; 21(5):793-8. PubMed ID: 12610176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Failure pattern and factors predictive of local failure in rhabdomyosarcoma: a report of group III patients on the third Intergroup Rhabdomyosarcoma Study.
    Wharam MD; Meza J; Anderson J; Breneman JC; Donaldson SS; Fitzgerald TJ; Michalski J; Teot LA; Wiener ES; Meyer WH
    J Clin Oncol; 2004 May; 22(10):1902-8. PubMed ID: 15143083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Primary chemotherapy in rhabdomyosarcomas and other malignant mesenchymal tumors of the orbit: results of the International Society of Pediatric Oncology MMT 84 Study.
    Rousseau P; Flamant F; Quintana E; Voute PA; Gentet JC
    J Clin Oncol; 1994 Mar; 12(3):516-21. PubMed ID: 7509854
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Pediatric rhabdomyosarcoma of the infratemporal fossa].
    Rozan O; Janot F; Oberlin O; Schwaab G; Quintana E; Tran Ba Huy P; Georges B; Luboinski B
    Ann Otolaryngol Chir Cervicofac; 2002 Sep; 119(4):195-201. PubMed ID: 12410115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of regional lymph node involvement in childhood extremity rhabdomyosarcoma.
    Mandell L; Ghavimi F; LaQuaglia M; Exelby P
    Med Pediatr Oncol; 1990; 18(6):466-71. PubMed ID: 2233517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Local therapy is critical in localised pelvic rhabdomyosarcoma: experience of the International Society of Pediatric Oncology Malignant Mesenchymal Tumor (SIOP-MMT) committee.
    Réguerre Y; Martelli H; Rey A; Rogers T; Gaze M; Ben Arush MW; Devalck C; Oberlin O; Stevens M; Orbach D
    Eur J Cancer; 2012 Sep; 48(13):2020-7. PubMed ID: 22154650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of relapse in pediatric localized extremity rhabdomyosarcomas correlated with locoregional therapies administered.
    Welmant J; Helfre S; Carton M; Bolle S; Minard-Colin V; Corradini N; Pannier S; Rome A; Mansuy L; Vérité C; Castex MP; Kerr C; Defachelles AS; Bernier V; Orbach D
    Strahlenther Onkol; 2021 Aug; 197(8):690-699. PubMed ID: 33914102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paratesticular rhabdomyosarcoma in children and adolescents-Outcome and patterns of relapse when utilizing a nonsurgical strategy for lymph node staging: Report from the International Society of Paediatric Oncology (SIOP) Malignant Mesenchymal Tumour 89 and 95 studies.
    Rogers T; Minard-Colin V; Cozic N; Jenney M; Merks JHM; Gallego S; Devalck C; Gaze MN; Kelsey A; Oberlin O; Stevens M; Spicer RD; Bergeron C; Martelli H
    Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28205365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. European intergroup studies (MMT4-89 and MMT4-91) on childhood metastatic rhabdomyosarcoma: final results and analysis of prognostic factors.
    Carli M; Colombatti R; Oberlin O; Bisogno G; Treuner J; Koscielniak E; Tridello G; Garaventa A; Pinkerton R; Stevens M
    J Clin Oncol; 2004 Dec; 22(23):4787-94. PubMed ID: 15570080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
    Rodeberg D; Arndt C; Breneman J; Lyden E; Donaldson S; Paidas C; Andrassy R; Meyer W; Wiener E
    J Pediatr Surg; 2005 Jan; 40(1):256-62. PubMed ID: 15868594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Rhabdomyosarcoma].
    Hosoi H; Tsuchiya K; Sugimoto T
    Gan To Kagaku Ryoho; 2007 Feb; 34(2):181-6. PubMed ID: 17301524
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion status in patients with lymph node-positive (N1) alveolar rhabdomyosarcoma is a powerful predictor of prognosis: Experience of the European Paediatric Soft Tissue Sarcoma Study Group (EpSSG).
    Gallego S; Zanetti I; Orbach D; Ranchère D; Shipley J; Zin A; Bergeron C; de Salvo GL; Chisholm J; Ferrari A; Jenney M; Mandeville HC; Rogers T; Merks JHM; Mudry P; Glosli H; Milano GM; Ferman S; Bisogno G;
    Cancer; 2018 Aug; 124(15):3201-3209. PubMed ID: 29797665
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality assessment of lymph node sampling in rhabdomyosarcoma: A surveillance, epidemiology, and end results (SEER) program study.
    Lobeck I; Dupree P; Karns R; Rodeberg D; von Allmen D; Dasgupta R
    J Pediatr Surg; 2017 Apr; 52(4):614-617. PubMed ID: 27642084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival benefit of post-mastectomy radiotherapy in breast carcinoma patients with T1-2 tumor and 1-3 axillary lymph node(s) metastasis.
    Duraker N; Demir D; Bati B; Yilmaz BD; Bati Y; Çaynak ZC; Sobutay E
    Jpn J Clin Oncol; 2012 Jul; 42(7):601-8. PubMed ID: 22511807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current concepts in the management of paratesticular rhabdomyosarcoma.
    Debruyne FM; Bökkerink JP; de Vries JD
    Prog Clin Biol Res; 1985; 203():507-17. PubMed ID: 3841696
    [No Abstract]   [Full Text] [Related]  

  • 19. Sarcoma of the prostate: a single institutional review.
    Janet NL; May AW; Akins RS
    Am J Clin Oncol; 2009 Feb; 32(1):27-9. PubMed ID: 19194120
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of three-dimensional conformal radiation therapy for patients with rhabdomyosarcoma.
    Wolden SL; La TH; LaQuaglia MP; Meyers PA; Kraus DH; Wexler LH
    Cancer; 2003 Jan; 97(1):179-85. PubMed ID: 12491519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.